Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ultragenyx Pharmaceutical

35.69
+0.71002.03%
Post-market: 35.63-0.0600-0.17%16:31 EDT
Volume:690.76K
Turnover:24.54M
Market Cap:3.35B
PE:-5.68
High:35.74
Open:35.00
Low:34.74
Close:34.98
Loading ...

Ultragenyx Pharmaceutical Q3 Net Loss Narrows, Revenue Rises; Shares Fall After Hours

MT Newswires Live
·
06 Nov 2024

Ultragenyx: Q3 Earnings Snapshot

Associated Press Finance
·
06 Nov 2024

Ultragenyx Pharmaceutical Q3 2024 GAAP EPS $(1.40) Beats $(1.53) Estimate, Sales $139.494M Beat $135.794M Estimate

Benzinga
·
06 Nov 2024

BRIEF-Ultragenyx Q3 EPS USD -1.4 Vs. IBES Estimate USD -1.45

Reuters
·
06 Nov 2024

Ultragenyx Pharmaceutical : Q3 2024 Total Revenue Grew 42% Versus Prior Year to $139 Mln

THOMSON REUTERS
·
06 Nov 2024

Ultragenyx Pharmaceutical Inc Q3 REV View $135.8 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
06 Nov 2024

Ultragenyx Pharmaceutical Inc: Reaffirmed 2024 Expected Total Revenue Guidance of $530 Mln to $550 Mln

THOMSON REUTERS
·
06 Nov 2024

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update

THOMSON REUTERS
·
06 Nov 2024

Ultragenyx Q3 Operating Expenses USD 271 Million

THOMSON REUTERS
·
06 Nov 2024

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update

GlobeNewswire
·
06 Nov 2024

Ultragenyx Pharmaceutical Inc expected to post a loss of $1.45 a share - Earnings Preview

Reuters
·
02 Nov 2024

What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity?

Insider Monkey
·
01 Nov 2024

Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update

GlobeNewswire
·
30 Oct 2024

Press Release: WisdomTree Announces Third Quarter 2024 Results

Dow Jones
·
25 Oct 2024

Recent 4.1% pullback isn't enough to hurt long-term Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders, they're still up 70% over 1 year

Simply Wall St.
·
23 Oct 2024

Ultragenyx Pharma Price Target Maintained With a $116.00/Share by Cantor Fitzgerald

Dow Jones
·
22 Oct 2024